EU Adds Another Rare Blood Condition as Side Effect of AstraZeneca Shot

A vial of AstraZeneca coronavirus vaccine is seen at a vaccination centre in Westfield Stratford City shopping centre, amid the outbreak of COVID-19 disease in London, Britain, on Feb. 18, 2021. Henry Nicholls/Reuters

Europe’s drug regulator on Friday identified another rare blood condition as a potential side effect of AstraZeneca’s COVID-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.

The European Medicines Agency’s (EMA) safety committee said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca’s vaccine, known as Vaxzevria.